Navigation Links
PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated

BOSTON, June 23 /PRNewswire-FirstCall/ -- According to new data from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, the number of new industry-sponsored clinical trial initiations, or starts, surged another 12 percent to a record high in 2007. PAREXEL's analysis shows that the biopharmaceutical industry submitted 662 commercial Investigational New Drug (IND) applications in support of new clinical studies for drugs in 2007, up from the previous record of 593 in 2006.

"The number of commercial IND submissions is a key measure of the number of clinical studies that are initiated by biopharmaceutical companies. IND submissions have been steadily increasing from 2004 to 2007, from 542 to 662 submissions, representing a 22 percent increase over this three year time period," said Mark Mathieu, Director of Publications at PAREXEL and Editor of PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook, 2008/2009.

Mr. Mathieu observed, "There has been a less consistent year-over-year pattern for commercial IND submissions of therapeutic biological products as compared with IND submissions related to drug products. PAREXEL data show that 83 commercial INDs were submitted for therapeutic biological products in 2007, which was down 27 percent from 114 submitted in 2006. The 114 INDs submitted in 2006 however, represented a 67 percent increase over submissions in 2005."

Oncology Studies Represent Largest Percentage of New Clinical Studies

According to PAREXEL data, new clinical studies of oncology drugs, which rose another 13 percent in 2007, comprised the largest percentage among all therapeutic areas for new clinical trial starts in 2007-nearly 15 percent of the total number of clinical trials that were initiated. Clinical trial starts involving neurology compounds spiked 45 percent in 2007, up from eight percent in 2006, and represented almost 11 percent of the total. Clinical trial starts for metabolism and endocrinology compounds represented another 11 percent of the total, although they were down 6 percent in 2007.

Overall Clinical Research Activity Just Below Record High

PAREXEL's analysis also includes an assessment of the number of active commercial INDs at the FDA Center for Drug Evaluation and Research (CDER), which is an indicator of overall clinical research activity. At the end of 2007, 5,417 active commercial INDs were being managed by CDER, compared to 5,445 at the end of 2006. "Our analysis shows that following a steady climb in recent years, the total number of active FDA-regulated INDs declined very slightly by a half percent in 2007, which was just below the record high," notes Mr. Mathieu.

About PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook

PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook, 2008/2009 is a leading compendium providing new insights into the trends that are reshaping the biopharmaceutical industry. Supported by thousands of graphs, illustrations, and analyses, the compendium provides the latest intelligence on every aspect of biopharmaceutical development-from product discovery to R&D performance and productivity to time-to-market trends.

With key analyses and contributions from leading consultancies and experts, the compendium provides real-world data and analyses, including:

-- New analysis of the countries in which biopharmaceutical companies are locating clinical studies

-- New global R&D spending trends and other international R&D data from key markets

-- International statistics on drug development output

-- Emerging data on worldwide and company-specific R&D pipelines and product launch trends

-- New analyses on drug development costs, development cycle times, and attrition rates

-- Drug approval statistics compiled from FDA, EMEA, and other regulatory agencies

PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2008/2009 (400+ pages) is published by Cambridge Healthtech Institute (CHI), an industry leader offering information to researchers and business experts from top pharmaceutical, biotech, and academic organizations. To order this compendium, which is available in hardcopy ($425 USD) and electronic format ($1,200, includes hardcover), visit the Educational Services section of the CHI website at or email

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 63 locations throughout 52 countries around the world, and has more than 7,600 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.


Jennifer Baird, Senior Director of Public Relations

PAREXEL International

Tel: +781-434-4409


Rebecca Passo

SHIFT Communications

Tel : +617-681-1817

Email :

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. PAREXEL Expands Global Clinical Pharmacology Capabilities
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. Stroke Study Reveals a Key Target For Improving Treatment
4. As Summer Heats Up, New Survey Reveals Need for Effective Sweat Treatments
5. Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection
6. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
7. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
8. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
9. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
10. Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
(Date:11/26/2015)... 26, 2015 --> ... SyMRI to find optimal contrast weighting of MRI for ... has signed a research agreement with SyntheticMR in order to ... SyMRI, it is possible to generate multiple contrast images from ... patient has left, thus making it possible to both fine ...
(Date:11/26/2015)... 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ... is expected to boost the market growth, as 3D bioprinting ... --> 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group ... group of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men ... prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, shown ... helped advance the healthcare industry as a whole through their advocacy and professional ...
(Date:11/26/2015)... ... 26, 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday ... the Black Friday and Cyber Monday massage chair sales to receive the ... and low to find the best massage chair deals, they can see all of ...
(Date:11/26/2015)... TX (PRWEB) , ... November 26, 2015 , ... PRMA ... On November 19, 2015, our surgeons performed their 6,000th free flap breast reconstruction surgery! ... “We wake up every day excited to rebuild lives and it’s an honor to ...
(Date:11/25/2015)... BROOK, Ill. (PRWEB) , ... November 25, 2015 ... ... larger and potentially more aggressive than those found on mammography, according to a ... MRI findings of additional cancers not seen on mammography may necessitate a change ...
Breaking Medicine News(10 mins):